Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression.
Benjamin HengAyse A BilginDavid B LovejoyVanessa X TanHeloisa H MilioliLaurence GluchSonia BustamanteTharani SabaretnamPablo MoscatoChai K LimGilles J GuilleminPublished in: Breast cancer research : BCR (2020)
Our findings suggest that KMO and KYNU inhibitors may represent new promising therapeutic targets for BrCa. We also showed that KP metabolite profiling can be used as an accurate biomarker for BrCa subtyping, as we successfully discriminated TN BrCa from other BrCa subtypes.